methamphetamine and pexacerfont

methamphetamine has been researched along with pexacerfont in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akhondzadeh, S; Moazen-Zadeh, E; Morabbi, MJ; Razaghi, E; Safi-Aghdam, H; Vousoghi, N; Zarrindast, MR	1

Trials

1 trial(s) available for methamphetamine and pexacerfont

Article	Year
Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. International clinical psychopharmacology, 2018, Volume: 33, Issue:2 Topics: Adult; Central Nervous System Stimulants; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Monitoring; Heroin; Humans; Male; Methamphetamine; Middle Aged; Psychiatric Status Rating Scales; Pyrazoles; Receptors, Corticotropin-Releasing Hormone; Severity of Illness Index; Substance Abuse Detection; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome; Triazines; Visual Analog Scale	2018

Article

Year

Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial.

International clinical psychopharmacology, 2018, Volume: 33, Issue:2

Topics: Adult; Central Nervous System Stimulants; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Monitoring; Heroin; Humans; Male; Methamphetamine; Middle Aged; Psychiatric Status Rating Scales; Pyrazoles; Receptors, Corticotropin-Releasing Hormone; Severity of Illness Index; Substance Abuse Detection; Substance Withdrawal Syndrome; Substance-Related Disorders; Treatment Outcome; Triazines; Visual Analog Scale

2018